Get the Stockscreener App
1.06
0.00%
0.00
After Hours:
1.04
-0.02
-1.89%
Revelation Biosciences Inc stock is traded at $1.06, with a volume of 8,618.
It is up +0.00% in the last 24 hours and up +8.16% over the past month.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
See More
Previous Close:
$1.06
Open:
$1.06
24h Volume:
8,618
Relative Volume:
0.17
Market Cap:
$4.14M
Revenue:
-
Net Income/Loss:
$-9.87M
P/E Ratio:
-0.0269
EPS:
-39.4678
Net Cash Flow:
$-8.76M
1W Performance:
-8.62%
1M Performance:
+8.16%
6M Performance:
-49.33%
1Y Performance:
-90.80%
1-Day Range:
$1.04
$1.0971
1-Week Range:
$1.03
$1.21
52-Week Range:
$0.875
$11.72
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
1.06 | 4.14M | 0 | -9.87M | -8.76M | -39.47 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revelation Biosciences Inc Stock (REVB) Latest News
Revelation Biosciences Inc (REVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc (REVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Revelation Biosciences Inc (REVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Revelation Biosciences Inc (REVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVB) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
REVB|Revelation Biosciences Inc|Price:1.060|Chg%:-0.030 - TradingKey
Revelation Biosciences Inc (REVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Weatherford Democrat
Three New Hires Get Revelation Biosciences Stock Awards Through 2028 - Stock Titan
Revelation Biosciences Adopts Stockholder Rights Plan to Protect Investors and Maximize Value - Minichart
Revelation Biosciences Adopts Stockholder Rights Protection Plan - TipRanks
Why Is Revelation Biosciences (NASDAQ:REVB) in Focus Today? - Kalkine Media
Revelation Biosciences Announces Adoption of Stockholder Rights Plan - ACCESS Newswire
New plan lets Revelation investors buy discounted shares if a buyer crosses 10% - Stock Titan
Revelation Biosciences (REVB) Hovers Near Support Amid Modest DeclineBollinger Expansion - dars.gov.et
REVB Q1 2026 Earnings: EPS Misses Estimates Significantly Amid No Revenue; Stock Rises 3.85%Earnings Cycle Outlook - DonanımHaber
Revelation Biosciences, Inc. Warrant 2022-10.01.27 on Revelatn Biosci Financial Disclosures & SEC Filings - TradingView
Price to sales forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Revelation Biosciences Inc. (REVB) Holds Steady Near Support as Micro-Cap Stock Shows Slight UptickATR Trailing Stop - dars.gov.et
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock Gains 6%Analyst Consensus Shift - dars.gov.et
Revelation Biosciences (REVB) Surges 6% as Biotech Stock Tests Key Resistance LevelJelly Roll Trade - DonanımHaber
Price to earnings forward of Revelation Biosciences, Inc. – BOATS:REVBW - TradingView
Revelation Biosciences, Inc. Actuals & Estimates (NASDAQ:REVB) - TradingView
ADTX Stock Price and Chart — OTC:ADTX - TradingView
Revelation Biosciences, Inc. Actuals & Estimates (BOATS:REVB) - TradingView
REVB Q1 2026 Earnings: EPS Miss Widens Loss, No Revenue Reported as Stock DeclinesLow Growth Earnings - dars.gov.et
REVB Forecast — Price Target — Prediction for 2027 - TradingView
Revelation Biosciences Inc (REVBW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Amends Executive Agreements and Bylaws, Announces CEO and CFO Changes – June 2026 - Minichart
Revelation Biosciences Updates Executive Contracts, Shareholder Actions - TipRanks
Revelation Biosciences updates employment agreements for CEO James Rolke and CFO Chester S. Zygmont, III - TradingView
Revelation Biosciences (NASDAQ: REVB) expands CEO/CFO protections and secures reverse split authority - Stock Titan
John Lowe, of Sayville, pleads guilty to insider trading scheme that netted $1 million in illegal profits - Newsday
Revelation Biosciences Inc (REVBW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Revelation Biosciences Inc (REVBW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVBW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Revelation Biosciences Inc (REVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revelation Biosciences Inc (REVBW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVBW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc - TradingKey
Revelation Biosciences Inc (REVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
REVB SEC FilingsRevelation Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; No Revenue ReportedEPS Revision Trend - newsline.com
REVB Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageCFO Commentary Report - newsline.com
Revelation Biosciences forms advisory board for AKI trial - Investing.com
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):